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Abstract
Sarcopenia has been defined as the age-related reduced skeletal muscle mass, 
strength, and physical capacity and is frequently associated with serious complica-
tions in patients with heart failure (HF). However, when HF progressed to end-
stage HF requiring advanced therapies, such as heart transplantation (HTx) and 
implantation of left ventricular assist device (LVAD), an even higher prevalence of 
sarcopenia has been reported in younger patients with end-stage HF than elderly 
patients with less advanced HF. Many literatures have reported that sarcopenia is 
greatly associated with high rates of morbidity and mortality after HTx and LVAD 
implantation. Therefore, therapeutic interventions to prevent and reverse sarcope-
nia, such as cardiac rehabilitation and nutrition supplementation, are important in 
patients with end-stage HF prior to HTx and LVAD implantation. Although moder-
ate or severe sarcopenia is a contraindication for HTx, the patients who can recover 
from sarcopenia after LVAD implantation would be considered eligible for HTx. 
Then, therapeutic options to reverse sarcopenia in patients supported with LVAD 
are also important to improve patient prognosis after LVAD implantation. In this 
review, the impacts of sarcopenia on prognosis after LVAD implantation and HTx 
and vice versa were summarized and therapeutic interventions to reverse sarcope-
nia before and after LVAD implantation are discussed.
Keywords: sarcopenia, end-stage heart failure, heart transplantation,  
left ventricular assist device, cardiac rehabilitation, nutrition supplementation
1. Introduction
Heart failure (HF) is a general acute and chronic disease expressing the 
advanced stage of various types of heart disease, and its prevalence is increasing 
year by year [1]. As the risk of HF increases with age [2], elderly patients occupy 
more than four-fifth of all patients with HF. HF may reduce organ and physical 
functional capacity and their daily life performance in patients. HF greatly affects 
physical function as well as body composition of skeletal muscle, which is greatly 
correlated with high rates of morbidity, hospitalization, and mortality [3, 4].
Sarcopenia is a syndrome characterized by general skeletal muscle mass loss and 
strength, which is related to poor outcomes and high mortality in patients with a 
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variety of underlying diseases [5]. Although sarcopenia has been first defined as an 
age-related syndrome, it was also frequently associated with serious complications 
in even younger patients with advanced stage of HF [6, 7]. The alteration in the 
skeletal muscle system in patients with HF plays the main role in developing many 
signs and symptoms related to HF [8, 9]. Then, sarcopenia may significantly greatly 
attribute to the poor prognosis in patients with HF than in those of the same age 
without HF [8]. The rate of sarcopenia in a patient with HF is reported to be higher 
at 19.5% than that in healthy individuals of the same age [10]. Although sarcopenia 
is more frequently associated with increasing age, an even higher prevalence of 47% 
has been reported in patients younger than 55 years with dilated cardiomyopathy 
[11]. Therefore, the patient population with end-stage HF requiring ventricular 
assist device (VAD) or heart transplantation (HTx) may be different from those 
with less advanced HF.
Even in younger patients with end-stage HF, metabolic abnormalities related 
to sarcopenia develop and affect renal and hepatic function [11]. Skeletal muscle, 
which is the greatest reservoir of protein, is easily wasted in catabolic illness 
including end-stage HF. However, therapeutic interventions to reverse progressive 
local and systemic catabolism in advanced HF are limited. Growth hormone (GH) 
administration and aerobic exercise rehabilitation are known to increase insulin-
like growth factor (IGF)-1 level in the blood and increase skeletal muscle volume in 
HF [12–14]. VAD implantation for bridge-to-transplantation (BTT) and destination 
therapy (DT) improves local and systemic metabolism probably due to corrected 
hemodynamics and tissue perfusion in patients with end-stage HF [15, 16]. Multiple 
literatures have reported that advanced strategies for HF, such as VAD implantation 
and HTx, provide optimal hemodynamic support and improve local and systemic 
metabolism, resulting in improvement of other organ function as well as physical 
capacity [17, 18].
Due to the great development in the field of left VAD (LVAD) in the past two 
decades, patients referred to this therapy are greatly increased. Although great 
advances in methodology and increased clinical experience in LVAD therapy 
had improved patient survival with end-stage HF over time, a certain amount of 
patients still has a high prevalence of mortality, comorbidity, and hospitalization 
after LVAD implantation, even in clinical trial settings [19]. As patients for DT are 
older and have more commodities before LVAD implantation than those for BTT, 
the use of LVAD for DT recently approved clinically worldwide may lead to higher 
mortality and morbidity in patients implanted with LVAD.
In this article, we review the impacts of both VAD and HTx on variables associ-
ated with sarcopenia as well as malnutrition in patients with end-stage HF and vice 
versa and discuss therapeutic interventions to reverse sarcopenia before and after 
LVAD implantation.
2. Diagnosis of sarcopenia
According to the consensus on definition and diagnosis by the European 
Working Group on Sarcopenia in Older People (EWGSOP), sarcopenia is defined by 
the presence of both reduced skeletal muscle mass and function as well as reduced 
physical performance (Figure 1) [20]. Skeletal muscle strength is assessed by 
handgrip strength (HGS), whereas physical performance is assessed by usual gait 
speed. In the presence of reduced skeletal muscle function, defined by a reduced 
gait speed (<0.8 m/s) and/or a reduced HGS (<26–30 kg for men and <16–20 kg 
for women), the diagnosis requires verification of reduced skeletal muscle mass. 
Currently, magnetic resonance imaging (MRI) and computed tomography (CT) 
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have been the gold standard to accurately measure the mass of a skeletal muscle as 
well as its density and fatty infiltration.
The HGS is an easy and simple tool but suffers from that peripheral muscle 
strength and function might improve after LVAD implantation and HTx as previ-
ously described [21, 22]. To resolve these limitations, investigators in the field 
of mechanical circulatory support and HTx have begun to estimate the grade of 
sarcopenia by evaluating the mass of skeletal muscles, such as psoas and pectoralis 
muscles with clinical prognosis. Positive results have been reported in patients 
undergoing invasive thoracic and abdominal surgeries [23–26] as well as in those 
with advanced HF [27–29]. CT scans provide precise identification and quantifica-
tion of individual skeletal muscle and fat tissue components [30–32].
Creatinine excretion rate index (CER index) in 24-hour urine collection is an 
easily measurable and less invasive classic marker of total-body skeletal muscle 
mass [33] and a reliable biomarker even in patients with advanced HF [34, 35]. 
Iwasaki et al. [36] reported that the CER index in patients with continuous-flow 
implantable LVAD (CF-LVAD) was significantly correlated with psoas and pectora-
lis muscles mass measured by CT scan.
3.  Impact of sarcopenia at pre-LVAD on outcome after LVAD implantation
Clinical studies of sarcopenia in patients with advanced heart failure referred for 
left ventricular assist device implantation or heart transplantation is summarized in 
(Table 1).
3.1 Skeletal muscle function
Chung et al. [21] examined the correlation of HGS with outcomes after LVAD 























Study Population No. Mean age (years) Gender Sarcopenia assessment Main findings Comment
Chung [21] Pre- and post LVAD 72 59
89%
male
Reduced HGS < 25% body 
weight
HGS < 25% at pre-LVAD 
associated
with increased operative 
mortality and postoperative 
complications.
HGS increased by 18.2 +/− 5.6% 
at 3 months (n 5 29) and 45.5 
+/− 23.9% at 6 months post-
LVAD implantation.
Reduced HGS in 22% pre-LVAD
Improved HGS in survivors at 3 and 
6 months post-LVAD.
HGS correlated with serum albumin 
level.
HGS was measured with Jamar 
dynamometer.
Khawaja [22] Pre-BTT LVAD 25 62
88%
male
HGS Mean HGS at pre-LVAD 35.8 
+/− 7.8 vs. 55.6 +/− 12.7 kg in 
control (no cardiac disease, 
nonsmokers) (P < 0.05) 
% increase in HGS at 6 mo 
on LVAD: +26.5 +/− 27.5% 
(P = 0.05)
LVAD implantation corrects GH/IGF-1 
signaling, improves muscle structure 
and function, and enhances oxidative 
muscle metabolism in patients with 
advanced HF
Heberton [37] Pre-DT LVAD 100 54
77%
male
Psoas muscle area on CT 
scan at L3-L4 level defined 
as lowest tertile for gender
Significant increase in 
composite endpoint of 
prolonged hospital-stay or 
inpatient mortality (P = 0.043)
Retrospective study
100 of 333 patients with usable CT 
scans
The psoas muscle area cut-off values for 
the lowest tertiles were 12.0 cm2 for men 
and 6.5 cm2 for women, resulting in 32 
sarcopenic patients (32%).
Teigen [32] Pre-BTT LVAD 143 60
89%
male
PMI and PHUm pre-LVAD Increased PMI and PHUm 
associated with a 27% 
reduction in the hazard of 
death after LVAD
For PMI, the estimated survival by 
tertile was the following: highest 
86%, middle 84%, and lowest 59% 
(P = 0.002 by log-rank test).





CSAbPm, HGS, MIP and 
MEP in waiting list group 
and after HTx
Reduced CSAbPm, HGS, MIP 
and MEP in waiting list group 
compared to healthy control
Increased CSAbPm, HGS, MIP 
and MEP in patients surviving 








































Study Population No. Mean age (years) Gender Sarcopenia assessment Main findings Comment
Cogswell [39] Pre-BTT LVAD Not defined Not defined Minnesota Pectoralis Risk 
Score (MPRS),
The calculated MPRS place each 
patient in the low, medium, or 
high-risk category and estimates 
survival probability at 30, 
60, and 365 days after LVAD 
implantation.
MPRS was calculated by a set of 
predictors, such as a PHUm, PMI, 
African American race, creatinine, total 
bilirubin, body mass index, bridge to 
transplant, and the presence or absence 
of contrast.
Receiver-operating characteristic curves 
for 30-, 90-, and 365-day survival were 
generated. The area under the curve for 
the model at 30, 90, and 365 days was 
0.78, 0.76, and 0.76, respectively.
Tsuji [40] Pre-BTT LVAD 78 42
71%
male
Skeletal muscle index (SMI) 
on CT scan at L3 level
Muscle wasting was associated 
with post-LVAD mortality 
(hazard ratio: 4.32; 95% CI: 
1.19–20.2)
The SMI cut-off values for the lowest 
tertiles were 36.7 cm2/m2 for men and 
28.2 cm2/m2 for women, resulting in 26 
patients (33.3%) with muscle wasting.
Iwasaki [36] Pre-BTT LVAD 147 44
72%
male
Creatinine excretion rate 
(CER) index
A low CER index was an 
independent predictor of 
intracranial hemorrhage in 
patients receiving a CF-iLVAD
CER index = [Cr]urine×24-h urine 
volume/body weight
Cogswell [41] Pre-LVAD 276 61
84%
male
PMI Patients in the low PMI group 
associated with post-LVAD 
mortality irrespectively of 
INTERMACS profile, but 
INTERMACS 3 and 4 patients 
in the high PMI groups had 
the highest survival on LVAD 
support
Patients with the largest deterioration in 
renal function (highest slope) between 
−365 and − 60 days before LVAD were 
more likely to be INTERMACS 1 and 2 
at the time of LVAD implantation.
Abbreviations: LVAD left ventricular assist device, HGS handgrip strength, BTT bridge to transplant,, GH: growth hormone, IGF-1; insulin-like growth factor, DT destination therapy, CT computed 
tomography, PMI Unilateral Pectoralis muscle mass indexed to BSA, PHUm pectoralis muscle mean Hounsfield unit, HTx heart transplantation, CSAbPm cross-sectional area of the bilateral psoas major 
muscle, MIP and MEP the maximum inspiratory and expiratory pressure body surface area, CI confidence interval, Cr serum creatinine.
Table 1. 
Clinical studies of sarcopenia in patients with advanced heart failure referred for left ventricular assist device implantation or heart transplantation.
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mortality. Khawaja et al. [22] reported that patients with advanced HF had signifi-
cantly lower HGS prior to CF-LVAD implantation compared to healthy controls and 
that the average HGS increased greater than 25% after 6 months after CF-LVAD 
implantation.
3.2 Skeletal muscle mass measurement
Heberton et al. [37] first introduced the assessment of skeletal muscle mass in 
the field of LVAD therapy and reported that sarcopenia by measuring psoas muscle 
area at L3-L4 vertebrae was significantly related to longer hospital stay and higher 
mortality after implantation of HeartMate II LVAD. On the other hand, Teigen et al. 
reported that pectoralis muscle mass and tissue quality by measuring Hounsfield 
units (PHUm) and size-indexed to body surface area were highly associated 
with post-LVAD mortality and surpassed any other variables in the University of 
Minnesota dataset [32]. This group further added an external dataset to create a 
user-friendly, multivariable post-LVAD mortality-prediction score, the so-called 
the Minnesota Pectoralis Risk Score (MPRS) [39]. This final model included PHUm, 
pectoralis muscle index (PMI), African American race, serum creatinine and total 
bilirubin, body mass index (BMI), BTT or DT, and the presence or absence of 
contrast. The estimated 1-year survival for patients after LVAD implantation by 
MPRS risk category (tertiles) was the following—low, medium, and high risks were 
95, 79, and 58%, respectively (P < 0.0001 by log-rank test). These skeletal muscle 
measures appear to add important prognostic value to pre-LVAD risk assessment 
[39]. A further study by them [41] described that INTERMACS 3 and four patients 
with the highest PMI had the best survival after CF-LVAD implantation. Tsuji et 
al. [40] also reported that muscle wasting defined by skeletal muscle index on CT 
scan at L3 level was also associated with post-LVAD mortality. From these findings, 
CT scan quantification of sarcopenia may help us to identify the optimal timing of 
LVAD implantation.
3.3 Creatinine excretion rate index
Iwasaki et al. [36] reported that reduced CER index was significantly related to a 
higher rate of mortality and intracranial hemorrhage after CF-LVAD implantation. 
Preoperative reduced CER index might be an independent predictor of intracranial 
hemorrhage after CF-LVAD implantation.
4.  Impact of sarcopenia as well as malnutrition at pre-HTx on outcome 
after HTx
4.1 Sarcopenia and indication for HTx
The donor heart shortage restricts HTx to a small portion of potential recipi-
ents. Moreover, serious complications accompanied with patients with end-stage 
HF, such as sarcopenia, systemic infection, and irreversible renal and hepatic 
dysfunction, more greatly affect patient prognosis after HTx than other cardiac 
surgery, because HTx recipients need immunosuppressive medication to prevent 
allograft rejection. Therefore, HTx is a treatment option for a few carefully selected 
patients with end-stage HF. The number of patients above the age of 60 years being 
transplanted has increased over the past 10 years. And recent post-HTx survival 
in patients aged between 60 and 69 years has been satisfactory. However, 5-year 
mortality in those aged 70 years and older are significantly poorer compared with 
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those aged between 18 and 59 years. Therefore, recipients aged older than 70 years 
are less acutely ill, have fewer comorbidities, and are less likely to have durable 
LVAD support for BTT [42]. Therefore, usually moderate or severe sarcopenia, as 
well as frailty, might be a contraindication for HTx. However, LVAD implantation in 
patients with frailty could be applicable as a bridge to candidacy. Patients who can 
recover from a frail state after LVAD implantation presumably after a certain period 
of physical rehabilitation and nutrition supplementation would then be considered 
eligible for HTx. This means that a sarcopenia patient who is firstly likely to survive 
LVAD implantation and secondly to reverse his/her frailty or sarcopenia can be a 
potential candidate for HTx [43]. For these reasons, there has been no published 
data concerning the impacts of real sarcopenia on outcomes after HTx.
4.2  Impact of malnutrition and physical rehabilitation at before and after HTx 
on exercise capacity post-HTx
Although previous studies have shown that the recipients exhibit improvements 
in exercise capacity and physical performance after HTx, the recipients often have 
a lower exercise capacity than normal healthy controls of the same age and gender 
soon and long after HTx.
Yanase et al. [44] investigated the effects of the recipient and donor predictive 
risk factors on the patient’s exercise capacity early after HTx. In this study, 3-month 
rehabilitation exercise training significantly increased peak VO2 irrespective of 
the main recipient or donor risk predictive factors on post-HTx survival, which 
included paracorporeal or implantable LVAD, and several marginal donor heart 
risk factors. Only younger recipient age and better several nutrition factors, such as 
higher choline esterase and higher blood lymphocyte count, at the entry of 3-month 
exercise program were significantly associated with higher peak VO2 at the entry 
and the end of the 3-month training program. These data suggested that nutrition 
management and rehabilitation at the bedside prior to starting the exercise training 
program play a significant role in increasing peak VO2 at the entry of the rehabilita-
tion program.
5. Impact of LVAD implantation on sarcopenia
As mentioned earlier, many investigators have shown that sarcopenia was 
associated with increased comorbidity and mortality after implantation of LVAD. 
On the other hand, only limited studies concerning the impact of LVAD implanta-
tion on sarcopenia have been available. Several investigators reported improvement 
of HGS after implantation of CF-LVAD [21, 22]. Although it has been reported that 
frailty prior to BTT LVAD implantation is associated with an increased post-LVAD 
morbidity and mortality, it has also been reported that frailty is reversible in most 
patients who survive the perioperative period [45, 46]. Maurer et al. [47] assessed 
reversal of frailty in 29 elderly frail LVAD recipients with a mean age of 71 years. 
Although frailty improved overall, 53% of the patients remained frail 6 months 
after LVAD implantation. These data suggested that frailty may be less reversible in 
aged patients supported with LVAD.
Multiple studies have shown that implantation of LVAD not only provides 
adequate hemodynamic support but also improves renal and liver function and 
psychical capacity especially after receiving physical rehabilitation. However, there 
are multifactorial limitations to exercise in patients supported with LVAD [38]. 
Although LVAD implantation improves hemodynamics in end-stage HF patients 
at rest, the device is unable to provide full circulatory support during exercise, 
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especially in patients with CF-LVAD. Thus, significant limitations in exercise capac-
ity persist soon and long after CF-LVAD implantation. Maximizing LV unloading 
and improving native myocardial function in association with an automated 
increase in LVAD speed could provide an increase in maximal exercise capacity 
in patients with the old-type pulsatile implantable LVAD. However, CF-LVAD can 
provide only partial improvement in maximal exercise capacity. Further studies are 
needed regarding the role of RV function, recovery of native cardiac function, the 
role of rehabilitation and nutrition intervention, changes in skeletal muscle func-
tion after CF-LVAD, and their contribution to endurance exercise [38].
6. Impact of HTx on sarcopenia
Fernandes et al. [48] investigated the impact of HTx on the recovery of periph-
eral and respiratory muscle mass and strength in patients with congestive HF. They 
showed significant decreases in a cross-sectional area of the bilateral psoas major 
muscle (CSAbPm), a bilateral HGS, and the maximum inspiratory and expiratory 
pressure (MIP and MEP) in patients on the waiting list compared with the healthy 
controls with normal cardiac function. They also found significant increases during 
waiting for HTx to 6- and 18-month post-HTx in the CSAbPm (1305.4 vs. 1458.1 vs. 
1431.3 mm2, respectively), bilateral HGS (27.3 vs. 30.2 vs. 34.7 kg/f, respectively), 
MIP (59.5 vs. 85.5 vs. 90.9 cmH2O, respectively), and MEP (79.5 vs. 93.2 vs. 101.8 
cmH2O, respectively). These results revealed that patients recovered peripheral and 
respiratory muscle mass and strength early after HTx. However, Schaufelberger  
et al. [49] demonstrated that intrinsic abnormalities in skeletal muscle found before 
HTx remained 6–9 months after HTx and might contribute to a reduced exercise 
capacity and muscle strength in these patients, in contrast to the former paper’s 
findings.
7. Management of sarcopenia after LVAD implantation
As mentioned earlier, sarcopenia is a strong negative predictor on outcome after 
LVAD implantation and HTx. Therefore, sarcopenia is one of the main therapeutic 
targets in patients with end-stage HF referred to LVAD implantation and HTx to 
avoid related comorbidity and to improve prognosis post-LVAD implantation and 
post-HTx. Although moderate or severe sarcopenia as well as frailty is a contrain-
dication for HTx, patients who can reverse frail after LVAD implantation would be 
considered eligible for HTx. Therefore, to further improve outcomes after LVAD 
implantation or HTx, therapeutic management for sarcopenia should be established 
in patients supported with LVAD as well as those prior to LVAD implantation. As 
the management of sarcopenia in patients prior to LVAD implantation might be the 
same in medically treated patients with end-stage HF and has been previously well 
discussed in many previous literatures, those for patients supported with CF-LVAD 
will be discussed in this review.
According to the pathophysiological factors involved in the pathogenesis of 
sarcopenia, therapeutic approaches for sarcopenia are summarized in Figure 2. 
Although Khawaja et al. [22] reported that CF-LVAD implantation corrects  
GH/IGF-1 signaling and improves muscle structure and function, only limited data 
were available regarding anti-inflammation strategies and hormonal therapies, 
such as GF/IGF-1 and ghrelin administration for sarcopenia in patients supported 
with LVAD. Therefore, exercise training and nutrition supplementation in patients 
supported with LVAD are reviewed in this review.
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7.1 Exercise training (rehabilitation) in LVAD patients
Generally, HTx or LVAD recipients attend a cardiac rehabilitation program to 
promote recovery after surgery. Such rehabilitation programs consist of standardized 
sessions of physical exercise training, with the same intensity and duration regardless 
of HTx or LVAD implantation. However, surgical indication and method, individual 
medical and surgical therapies, and possible adverse events after surgery might affect 
the efficacy of cardiac rehabilitation differently in HTx and LVAD patients. If this 
occurs, rehabilitation programs better tailored to LVAD patients should be designed.
Yanase et al. [44] reported that short term, such as 3-month rehabilitation  
program, could significantly increase post-HTx exercise capacity irrespective of 
age, gender, type of LVAD, and underlying disease. But, even in those patients, 
better several nutrition factors at exercise program admission were significantly 
associated with peak VO2 at the end of the exercise program. Therefore, nutrition 
supplementation during LVAD support might be also essential to improve exercise 
capacity post-HTx as well as exercise training. However, there are no guidelines 
regarding the best way to cardiac exercise prescription, especially for CF-LVAD 
patients. As a result, LVAD patients currently undergo rehabilitation protocols 
designed for other types of cardiovascular diseases or cardiac surgeries.
As patients receiving LVAD are deeply deconditioned due to advanced HF, it 
is recommended that patients with sarcopenia as well as frailty are admitted to an 
in-patient rehabilitation program soon after implanting LVAD. Alsara et al. [50] 
reviewed the literatures regarding cardiac rehabilitation in patients supported 
with LVAD and concluded that exercise training is safe and recommended early 
mobilization between 7 and 10 days post-LVAD and treadmill exercise training 
beginning at 21 days post-LVAD. However, there is very few information regarding 
the improvements derived from exercise training in LVAD patients.
Currently, pulsatile-flow LVADs (PF-LVADs) are seldom used as durable support 
in patients with end-stage HF, but they have a pneumatically/electrically driven 
ventricle operating in the complete fill/ and empty mode. Therefore, cardiac output 
during exercise will increase by an automatic increase in pump rate responding to 
an increase in left ventricular (LV) preload. PF-LVADs work independently from LV 
afterload and produce a maximal cardiac output of 10 liters/min with a pump rate 
Figure 2. 
Sarcopenia pathogenesis and therapeutic approaches: GH growth hormone, IGF-1 insulin-like growth factor-1.
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of 120 beats/min [51]. On the other hand, the CF-LVAD has no inflow or outflow 
valves, unloads the ventricle in both systole and diastole, and operates at a fixed 
pump speed. The two types of CF-LVADs are axial and centrifugal. Pump flow 
changes according to the differential pressure between the inflow and outflow can-
nulas. The sensitivity of axial and centrifugal pumps to changes in preload is simi-
lar, whereas centrifugal pumps are more sensitive to afterload [52]. During exercise, 
pump flow increases in the CF-LVAD according to changes in LV preload and 
afterload. For example, RV failure decreases LV preload and high systemic pressure 
decreases LV afterload, resulting in reduced pump flow. Therefore, CF-LVAD can-
not fully increase pump flow with exercise, whereas PF-LVAD can do so.
Haft et al. [53] reported the differences in the exercise hemodynamic responses 
between PF-LVAD and CF-LVAD. Peak VO2 as well as resting central venous 
pressure, mean arterial pressure, and pulmonary capillary wedge pressure were 
similar and pump flow increased peak VO2 in both groups. However, the increase in 
pump flow was approximately 20% greater in the PF-LVAD than in the CF-LVAD. 
Moreover, the significance of this finding is unclear because the pump flow through 
for the CF-LVAD is not directly measured but only estimated. Martina et al. [54] 
reported that patients supported with CF-LVAD showed a mean peak VO2 of 
18 mL/kg/min (55% of predicted) and a mean total maximum cardiac output of 
8.5 liters/min. From these studies, patients supported with CF-LVAD may have 
a similar peak VO2 independently of the type of CF-LVAD. Although maximum 
cardiac output increases with exercise in patients supported with CF-LVAD, it does 
not reach levels found in healthy individuals with normal cardiac function.
Many factors, such as underlying heart disease, native heart function, especially 
right ventricular function, both ventricular morphology, co-existing arrhythmia, 
type of LVAD, rehabilitation protocol, and nutrition intervention may influence 
the effect of cardiac rehabilitation on improvement in exercise capacity and recov-
ery from sarcopenia. Therefore, individualized exercise prescriptions leading to 
optimal improvements in exercise capacity in patients supported with CF-LVAD are 
not well known and should be established in the field of LVAD therapy [47].
7.2 Nutrition
There is no doubt that malnutrition is involved in the pathogenesis of sarcope-
nia, and that it contributes to the poor muscle function observed in patients with 
end-stage HF, particularly in frail elderly patients. In general, the proposition of 
nutritional interventions should be based on the delivery of an adequate energy 
supply and on the supplementation of specific nutrients as an effective treatment 
in preventing and/or reversing sarcopenia in patients with advanced HF. However, 
there are very few literatures regarding the recovery from sarcopenia by nutrition 
interventions particularly in patients supported by LVAD.
8. Conclusion
Sarcopenia as well as frailty is a strong negative predictor on outcome after 
LVAD implantation and HTx. Assessment of skeletal muscle function such as HGS 
and gait speed, and measurement of skeletal muscle mass and CER index prior to 
surgery are useful tools to predict patient’s outcome after LVAD implantation and 
HTx. Therefore, therapeutic strategies to reverse sarcopenia prior to surgery and 
after LVAD implantation are important to improve their outcomes. However, many 
factors, such as the indication, surgical method, postoperative therapies, and pos-
sible adverse events, might affect the efficacy of cardiac rehabilitation and nutrition 
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supplementation on quality of life as well as survival differently in HTx and LVAD 
patients. Therefore, individualized exercise prescriptions and nutrition interven-
tions leading to the reversal of sarcopenia as well as frailty in patients undergoing 
and supported with CF-LVAD should be established in the near future.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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